Skinny Label and Induced Infringement: The Saga Continues
FDA Law Blog: Biosimilars
MAY 11, 2023
GSK skinny label case , the U.S. In the brief , the Government takes a strong position, stating “[t]he court of appeals’ holding that respondents presented sufficient evidence of petitioner’s intent to induce infringement is erroneous and warrants this Court’s review.”
Let's personalize your content